| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adverse event development in clinical oncology trials
|
Walraven, Iris
|
|
2016
|
17 |
7 |
p. e263
|
artikel
|
| 2 |
Adverse event development in clinical oncology trials
|
Schmoor, Claudia
|
|
2016
|
17 |
7 |
p. e263-e264
|
artikel
|
| 3 |
Adverse event development in clinical oncology trials – Authors' reply
|
Thanarajasingam, Gita
|
|
2016
|
17 |
7 |
p. e264-e265
|
artikel
|
| 4 |
Age at cancer diagnosis and interpretation of survival statistics
|
Autier, Philippe
|
|
2016
|
17 |
7 |
p. 847-848
|
artikel
|
| 5 |
Anti-PD-L1 inhibitor durvalumab in bladder cancer
|
Brower, Vicki
|
|
2016
|
17 |
7 |
p. e275
|
artikel
|
| 6 |
2016 ASCO Annual Meeting
|
Lokody, Isabel
|
|
2016
|
17 |
7 |
p. 875-876
|
artikel
|
| 7 |
Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel
|
Lovett, Rosemary
|
|
2016
|
17 |
7 |
p. 872-873
|
artikel
|
| 8 |
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
|
Choueiri, Toni K
|
|
2016
|
17 |
7 |
p. 917-927
|
artikel
|
| 9 |
Cancer awareness to live happily ever after
|
Harding, Emilia
|
|
2016
|
17 |
7 |
p. 880-881
|
artikel
|
| 10 |
Cancer data in India show new patterns
|
Sharma, Dinesh C
|
|
2016
|
17 |
7 |
p. e272
|
artikel
|
| 11 |
Capecitabine and lapatinib treatment in head and neck cancer
|
Brower, Vicki
|
|
2016
|
17 |
7 |
p. e271
|
artikel
|
| 12 |
Carcinogenicity of drinking coffee, mate, and very hot beverages
|
Loomis, Dana
|
|
2016
|
17 |
7 |
p. 877-878
|
artikel
|
| 13 |
Challenges in breast and cervical cancer control in Japan
|
Sauvaget, Catherine
|
|
2016
|
17 |
7 |
p. e305-e312
|
artikel
|
| 14 |
Choosing frontline chemoimmunotherapy for CLL
|
Wiestner, Adrian
|
|
2016
|
17 |
7 |
p. 852-854
|
artikel
|
| 15 |
Combined BRAF and MEK inhibition in BRAF-mutant NSCLC
|
Rivalland, Gareth
|
|
2016
|
17 |
7 |
p. 860-862
|
artikel
|
| 16 |
Correction to Lancet Oncol 2016; 17: 953
|
|
|
2016
|
17 |
7 |
p. e270
|
artikel
|
| 17 |
Correction to Lancet Oncol 2016; 17: 888, 890, 892
|
|
|
2016
|
17 |
7 |
p. e270
|
artikel
|
| 18 |
Correction to Lancet Oncol 2015; 16: 1479
|
|
|
2016
|
17 |
7 |
p. e270
|
artikel
|
| 19 |
Correction to Lancet Oncol 2016; 17: 351
|
|
|
2016
|
17 |
7 |
p. e270
|
artikel
|
| 20 |
Correction to Lancet Oncol 2016; 17: 995, 1002
|
|
|
2016
|
17 |
7 |
p. e270
|
artikel
|
| 21 |
Correction to Lancet Oncol 2014; 16: 767
|
|
|
2016
|
17 |
7 |
p. e270
|
artikel
|
| 22 |
Correction to Lancet Oncol 2016; 17: 431, 434, 435
|
|
|
2016
|
17 |
7 |
p. e270
|
artikel
|
| 23 |
Dabrafenib plus trametinib in patients with previously treated BRAF V600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
|
Planchard, David
|
|
2016
|
17 |
7 |
p. 984-993
|
artikel
|
| 24 |
Defining the role of radiotherapy for retroperitoneal sarcoma
|
Baldini, Elizabeth H
|
|
2016
|
17 |
7 |
p. 857-859
|
artikel
|
| 25 |
Digestive Disease Week 2016
|
Brierley, Rob
|
|
2016
|
17 |
7 |
p. 874
|
artikel
|
| 26 |
Extending aromatase inhibitor adjuvant therapy to 10 years
|
Baker, Holly
|
|
2016
|
17 |
7 |
p. e275
|
artikel
|
| 27 |
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
|
Eichhorst, Barbara
|
|
2016
|
17 |
7 |
p. 928-942
|
artikel
|
| 28 |
Garlic: a stake through the heart of cancer?
|
de Giorgio, Alex
|
|
2016
|
17 |
7 |
p. 879-880
|
artikel
|
| 29 |
Good outcomes for lymphoma treatment during pregnancy
|
Brower, Vicki
|
|
2016
|
17 |
7 |
p. e273
|
artikel
|
| 30 |
Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials
|
Ghislain, Irina
|
|
2016
|
17 |
7 |
p. e294-e304
|
artikel
|
| 31 |
Immunotherapy for small-cell lung cancer
|
Li, Yangqiu
|
|
2016
|
17 |
7 |
p. 846-847
|
artikel
|
| 32 |
Improved quality of life is the way to longer life
|
Procopio, Giuseppe
|
|
2016
|
17 |
7 |
p. 862-863
|
artikel
|
| 33 |
Long waiting times for test results for NHS patients
|
Burki, Talha Khan
|
|
2016
|
17 |
7 |
p. e274
|
artikel
|
| 34 |
Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management
|
Baldwin, David R
|
|
2016
|
17 |
7 |
p. 849-850
|
artikel
|
| 35 |
LUX-Lung 7: is there enough data for a final conclusion?
|
Di Maio, Massimo
|
|
2016
|
17 |
7 |
p. e266
|
artikel
|
| 36 |
LUX-Lung 7: is there enough data for a final conclusion?
|
Orlandi, Armando
|
|
2016
|
17 |
7 |
p. e267-e268
|
artikel
|
| 37 |
LUX-Lung 7: is there enough data for a final conclusion?
|
Hu, Chunhong
|
|
2016
|
17 |
7 |
p. e266-e267
|
artikel
|
| 38 |
LUX-Lung 7: is there enough data for a final conclusion? – Author's reply
|
Park, Keunchil
|
|
2016
|
17 |
7 |
p. e268-e269
|
artikel
|
| 39 |
National Health Service England introduces dose banding
|
Mayor, Susan
|
|
2016
|
17 |
7 |
p. e271
|
artikel
|
| 40 |
New options in treatment of advanced renal cancer
|
Bex, Axel
|
|
2016
|
17 |
7 |
p. 850-852
|
artikel
|
| 41 |
New therapy for acute lymphoblastic leukaemia
|
Wilkinson, Emma
|
|
2016
|
17 |
7 |
p. e276
|
artikel
|
| 42 |
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|
Antonia, Scott J
|
|
2016
|
17 |
7 |
p. 883-895
|
artikel
|
| 43 |
Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial
|
Walter, Joan E
|
|
2016
|
17 |
7 |
p. 907-916
|
artikel
|
| 44 |
One way: a journey to this moment
|
Burki, Talha Khan
|
|
2016
|
17 |
7 |
p. 881
|
artikel
|
| 45 |
Outcomes for girls without HPV vaccination in Japan
|
Tanaka, Yusuke
|
|
2016
|
17 |
7 |
p. 868-869
|
artikel
|
| 46 |
Paediatric lymphocyte-predominant Hodgkin's lymphoma
|
Burki, Talha Khan
|
|
2016
|
17 |
7 |
p. e272
|
artikel
|
| 47 |
Pancreatic cancer: cause for optimism?
|
The Lancet Oncology,
|
|
2016
|
17 |
7 |
p. 845
|
artikel
|
| 48 |
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
|
Goldberg, Sarah B
|
|
2016
|
17 |
7 |
p. 976-983
|
artikel
|
| 49 |
Phosphenes in patients receiving radiotherapy
|
Thariat, Juliette
|
|
2016
|
17 |
7 |
p. 869-871
|
artikel
|
| 50 |
Physical frailty in survivors of haemopoietic cell transplant
|
Brower, Vicki
|
|
2016
|
17 |
7 |
p. e274
|
artikel
|
| 51 |
Playing Where's Wally with cancer
|
Denny, Victoria
|
|
2016
|
17 |
7 |
p. 882
|
artikel
|
| 52 |
Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database
|
Nussbaum, Daniel P
|
|
2016
|
17 |
7 |
p. 966-975
|
artikel
|
| 53 |
Prophylactic cranial irradiation for patients with lung cancer
|
Péchoux, Cécile Le
|
|
2016
|
17 |
7 |
p. e277-e293
|
artikel
|
| 54 |
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
|
Cella, David
|
|
2016
|
17 |
7 |
p. 994-1003
|
artikel
|
| 55 |
Refugee children with cancer in Turkey
|
Kebudi, Rejin
|
|
2016
|
17 |
7 |
p. 865-867
|
artikel
|
| 56 |
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
|
Seiwert, Tanguy Y
|
|
2016
|
17 |
7 |
p. 956-965
|
artikel
|
| 57 |
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
|
Weber, Jeffrey S
|
|
2016
|
17 |
7 |
p. 943-955
|
artikel
|
| 58 |
Sequential immunotherapy regimens—expect the unexpected
|
Serra-Bellver, Patricio
|
|
2016
|
17 |
7 |
p. 854-855
|
artikel
|
| 59 |
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
|
Abdel-Fatah, Tarek M A
|
|
2016
|
17 |
7 |
p. 1004-1018
|
artikel
|
| 60 |
SPAG5: the ultimate marker of proliferation in early breast cancer?
|
Bertucci, François
|
|
2016
|
17 |
7 |
p. 863-865
|
artikel
|
| 61 |
Stronger correlation of surrogate endpoints with survival needed
|
Carlson, Robert H
|
|
2016
|
17 |
7 |
p. e273
|
artikel
|
| 62 |
Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5
|
Trama, Annalisa
|
|
2016
|
17 |
7 |
p. 896-906
|
artikel
|
| 63 |
The direct-to-consumer genetics debate
|
Kill, Andy
|
|
2016
|
17 |
7 |
p. e265
|
artikel
|
| 64 |
The promise of immunostimulatory antibodies in head and neck cancer
|
Machiels, Jean-Pascal H
|
|
2016
|
17 |
7 |
p. 856-857
|
artikel
|
| 65 |
Trends in immunotherapy for brain metastases
|
Rosell, Rafael
|
|
2016
|
17 |
7 |
p. 859-860
|
artikel
|
Tijdschrift beschrijving